ST-617 is under clinical development by Supportive Therapeutics and currently in Phase I for Chemotherapy Induced Oral Mucositis. According to GlobalData, Phase I drugs for Chemotherapy Induced Oral Mucositis have a 96% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ST-617’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ST-617 overview
ST-617 is under development for the prevention and treatment of chemoradiation therapy (CRT) induced oral mucositis (OM). It is administered through oral route in the form of suspension. It is a formulation of dithiolethine.
Supportive Therapeutics overview
Supportive Therapeutics is a biopharmaceutical company engaged in research and development of novel medicines for reducing the side effects of cancer treatments. The company is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of ST-617’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
